I am an expert in statistical methodology within the Biostatistics department at Novo Nordisk. My expertise lies in quantitative evidence synthesis, data fusion, HTA and observational science. I am currently developing and implementing innovative statistical methods for the enrichment of clinical trials with real-world data sources and for the transportability and generalizability of research data.
I have ample experience as a statistician, researcher and statistical consultant, providing support to the pharmaceutical, biotechnology, and healthcare consultancy sectors. Prior to my current role, I was lead statistician for health technology assessment at Bayer Pharmaceuticals. Prior to that, I was an independent contractor providing statistical support to contract research organizations such as IQVIA and ICON plc, and public bodies such as SickKids.
See my Google Scholar profile for an updated list of publications.
PhD Statistical Science
University College London
MRes Financial Computing
University College London
MSc Machine Learning
University College London
BSc Mathematics and Physics
University of Bath
My research lies on the interface between statistics and health technology assessment, involving both methodological and applied problems. My primary interests are the development of statistical methodology to compare treatments in the absence of head-to-head clinical trials, adjusting for differences in patient populations and overcoming limited access to subject-level data.
Current interests: indirect treatment comparisons, covariate adjustment, transportability, estimands

ISPOR Europe 2025
Nov 12, 2025

ISPOR Europe 2025
Nov 10, 2025

10th EFSPI Regulatory Statistics Workshop
Sep 10, 2025

46th Conference of the International Society for Clinical Biostatistics
Aug 25, 2025

ASA Biopharmaceutical Section Webinar Series
Jun 20, 2025